QR-koodi

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

Background: Liquid biopsy (LB) can detect actionable genomic alterations in plasma circulating tumor circulating tumor DNA beyond tissue testing (TT) alone in advanced non-small cell lung cancer (NSCLC) patients. We estimated the cost-effectiveness of adding LB to TT in the Canadian healthcare syste...

Täydet tiedot

Tallennettuna:
Päätekijät: Doreen A. Ezeife, Eldon Spackman, Rosalyn A. Juergens, Janessa J. Laskin, Jason S. Agulnik, Desiree Hao, Scott A. Laurie, Jennifer H. Law, Lisa W. Le, Lesli A. Kiedrowski, Barbara Melosky, Frances A. Shepherd, Victor Cohen, Paul Wheatley-Price, Rachel Vandermeer, Janice J. Li, Roxanne Fernandes, Aria Shokoohi, Richard B. Lanman, Natasha B. Leighl
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publishing 2022-07-01
Sarja:Therapeutic Advances in Medical Oncology
Linkit:https://doi.org/10.1177/17588359221112696
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia